The CEO of Moderna (NSDQ:MRNA) thinks the FDA could grant an EUA for its COVID-19 vaccine candidate in December, depending on whether it sees positive interim clinical results in November.
Moderna CEO Stéphane Bancel’s comments — made during The Wall Street Journal’s annual Tech Live conference yesterday and reported in the newspaper — suggest that the Cambridge, Mass.-based biotech company is on a similar timetable to Pfizer (NYSE:PFE).
Get the full story on our sister site Drug Discovery & Development.